RARITAN, New Jersey, June 12, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, ...
- Ortho's VITROS® SARS-CoV-2 antigen test can detect SARS-CoV-2 infection in asymptomatic individuals. - The low-cost VITROS antigen test can run up to 130 tests per hour and is a viable choice for ...
RARITAN, N.J., July 21 Ortho Clinical Diagnostics today announced the U.S. Food and Drug Administration (FDA) approval of the VITROS((R)) Anti-HCV assay for use on the VITROS 5600((R)) Integrated and ...
RARITAN, N.J., Feb. 26, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today ...
Ortho Clinical Diagnostics (OCD) today announced the launch of the VITROS® 4600 Chemistry System, a state-of-the-art analyzer that delivers high-quality, reliable test results for mid- to high-volume ...
RARITAN, N.J.- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced CE Mark for its next-generation VITROS® High Sensitivity Troponin I assay. This new assay is the latest ...
RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the first fully automated ...
Authorized for use in the U.S. in January 2021, Ortho's VITROS® SARS-CoV-2 Antigen Test offers reliable detection of SARS-CoV-2 in patients suspected of COVID-19 by their healthcare provider within ...
RARITAN, N.J., April 13, 2021 /CNW/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its ...
SAN DIEGO, July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo ...